

From: [Pauline Stoltzner](#)
To: [Pharmacy Services](#)
Subject: Caplyta formulary
Date: Tuesday, May 25, 2021 10:12:48 AM

To whom it may concern,

Over the past year I have used Caplyta with great success. The combination of having a really good metabolic profile and placebo like EPS/Akathisia makes it a perfect choice for many of the schizophrenia patients in my practice.

Therefore I am asking you to make Caplyta unrestricted and preferred on the Nevada Medicaid formulary.

Thank you,

Dr. Pauline Stoltzner
NV State Lic #APRN002457